Dimensional Fund Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-875,618
| Closed | -$3.24M | – | 3377 |
|
|
2017
Q4 | $3.24M | Buy |
875,618
+363,719
| +71% | +$1.49M | ﹤0.01% | 2747 |
|
|
2017
Q3 | $2.09M | Buy |
511,899
+414,019
| +423% | +$1.58M | ﹤0.01% | 2850 |
|
|
2017
Q2 | $364K | Buy |
97,880
+65,651
| +204% | +$260K | ﹤0.01% | 3136 |
|
|
2017
Q1 | $133K | Buy |
+32,229
| New | +$135K | ﹤0.01% | 3228 |
|
|
2016
Q4 | – | Sell |
-3,380
| Closed | -$33K | – | 3318 |
|
|
2016
Q3 | $33K | Hold |
3,380
| – | – | ﹤0.01% | 3264 |
|
|
2016
Q2 | $19K | Hold |
3,380
| – | – | ﹤0.01% | 3284 |
|
|
2016
Q1 | $26K | Hold |
3,380
| – | – | ﹤0.01% | 3283 |
|
|
2015
Q4 | $45K | Hold |
3,380
| – | – | ﹤0.01% | 3301 |
|
|
2015
Q3 | $56K | Hold |
3,380
| – | – | ﹤0.01% | 3336 |
|
|
2015
Q2 | $76K | Sell |
3,380
-1,297
| -28% | -$20.5K | ﹤0.01% | 3318 |
|
|
2015
Q1 | $46K | Hold |
4,677
| – | – | ﹤0.01% | 3312 |
|
|
2014
Q4 | $53K | Hold |
4,677
| – | – | ﹤0.01% | 3372 |
|
|
2014
Q3 | $54K | Hold |
4,677
| – | – | ﹤0.01% | 3393 |
|
|
2014
Q2 | $91K | Sell |
4,677
-23
| -0.5% | -$406 | ﹤0.01% | 3383 |
|
|
2014
Q1 | $84K | Hold |
4,700
| – | – | ﹤0.01% | 3406 |
|
|
2013
Q4 | $50K | Hold |
4,700
| – | – | ﹤0.01% | 3416 |
|
|
2013
Q3 | $58K | Sell |
4,700
-123
| -3% | -$1.29K | ﹤0.01% | 3436 |
|
|
2013
Q2 | $45K | Buy |
+4,823
| New | +$62K | ﹤0.01% | 3450 |
|
Dimensional Fund Advisors's CASC Position: Q1 2018 in Review
Dimensional Fund Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 875,618 shares — an estimated $3.24M sold.
Dimensional Fund Advisors first reported a position in CASC in Q2 2013 and held it in 18 quarters. The position peaked at $3.24M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Dimensional Fund Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Dimensional Fund Advisors sold 875,618 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $3.24M.
- Dimensional Fund Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
- Dimensional Fund Advisors's Cascadian Therapeutics, Inc. position peaked at $3.24M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Dimensional Fund Advisors's 13F filing for Q1 2018, filed 11 May 2018.